Targeting oncoproteins for degradation by small molecules in myeloid leukemia

References

• Hughes TP, Saglio G, Quintas-Cardama A, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015;29:1832–1838.
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14:141–154.
   PubMed Web of Science ®Google Scholar
• Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
   PubMed Web of Science ®Google Scholar
• Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129:3403–3406.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–309.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22:345–358.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547–555.
   PubMed Web of Science ®Google Scholar
• Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene. 2001;20:7146–7153.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328:240–243.
   PubMed Web of Science ®Google Scholar
• Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2002;99:3806–3811.
   PubMed Web of Science ®Google Scholar
• Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA. 1999;96:14807–14812.
   PubMed Web of Science ®Google Scholar
• Liang K, Volk AG, Haug JS, et al. Therapeutic targeting of MLL degradation pathways in MLL-rearranged Leukemia. Cell. 2017;168:59–72 e13.
   PubMed Web of Science ®Google Scholar
• Larrue C, Saland E, Boutzen H, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127:882–892.
   PubMed Web of Science ®Google Scholar
• Buchwald M, Pietschmann K, Muller JP, et al. Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia. 2010;24:1412–1421.
   PubMed Web of Science ®Google Scholar
• Buhrlage S, Weisberg E, Schauer N, et al. Inhibition of USP10 Induces Degradation of Oncogenic FLT3: a novel approach to therapy of leukemia. Blood. 2016;128:524.
   Web of Science ®Google Scholar
• Goussetis DJ, Gounaris E, Wu EJ, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 2012;120:3555–3562.
   PubMed Web of Science ®Google Scholar
• Mao JH, Sun XY, Liu JX, et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 2010;107:21683–21688.
   PubMed Web of Science ®Google Scholar
• Tsukahara F, Maru Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood. 2010;116:3582–3592.
   PubMed Web of Science ®Google Scholar
• Sun H, Kapuria V, Peterson LF, et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. 2011;117:3151–3162.
   PubMed Web of Science ®Google Scholar
• Huang H, Weng H, Dong B, et al. Oridonin triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia. Sci Rep. 2017;7:41525.
   PubMed Web of Science ®Google Scholar
• Lai AC, Toure M, Hellerschmied D, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807–810.
   PubMed Web of Science ®Google Scholar
• Yang G, Thompson MA, Brandt SJ, et al. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene. 2007;26:91–101.
   PubMed Web of Science ®Google Scholar
• Zhou B, Li H, Xing C, et al. Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia. Biochem Pharmacol. 2017;128:12–25.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao WL, Yan JS, et al. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ. 2007;14:306–317.
   PubMed Web of Science ®Google Scholar
• Kramer OH, Muller S, Buchwald M, et al. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. Faseb J. 2008;22:1369–1379.
   PubMed Web of Science ®Google Scholar
• Li Q, Kluz T, Sun H, et al. Mechanisms of c-Myc degradation by nickel compounds and hypoxia. PLoS One. 2009;4:e8531.
   PubMed Web of Science ®Google Scholar
• Huang HL, Weng HY, Wang LQ, et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 2012;11:1155–1165.
   PubMed Web of Science ®Google Scholar
• Winter GE, Buckley DL, Paulk J, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376–1381.
   PubMed Web of Science ®Google Scholar
• Saenz DT, Fiskus W, Qian Y, et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017;31:1951–1961.
   PubMed Web of Science ®Google Scholar
• Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27:2165–2176.
   PubMed Web of Science ®Google Scholar
• Grembecka J, Cierpicki T. Stabilizing the mixed lineage leukemia protein. N Engl J Med. 2017;376:1688–1689.
   PubMed Web of Science ®Google Scholar
• Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117:3286–3293.
   PubMed Web of Science ®Google Scholar
• Weisberg EL, Schauer NJ, Yang J, et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017;13:1207–1215.
   PubMed Web of Science ®Google Scholar
• Hatlen MA, Wang L, Nimer SD. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med. 2012;6:248–262.
   PubMedGoogle Scholar
• Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer. 2015;15:593–607.
   PubMed Web of Science ®Google Scholar
• Roderick JE, Tesell J, Shultz LD, et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014;123:1040–1050.]
   PubMed Web of Science ®Google Scholar
• Salvatori B, Iosue I, Djodji Damas N, et al. Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2. Genes Cancer. 2011;2:585–592.
   PubMedGoogle Scholar
• Luo H, Li Q, O’Neal J, et al. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005;106:2452–2461.
   PubMed Web of Science ®Google Scholar
• Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116–2125.
   PubMed Web of Science ®Google Scholar
• von der Lehr N, Johansson S, Wu S, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–1200.
   PubMed Web of Science ®Google Scholar
• Popov N, Wanzel M, Madiredjo M, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9:765–774.
   PubMed Web of Science ®Google Scholar
• Sun XX, He X, Yin L, et al. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc Natl Acad Sci USA. 2015;112:3734–3739.
   PubMed Web of Science ®Google Scholar
• Pan J, Deng Q, Jiang C, et al. USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer. Oncogene. 2015;34:3957–3967.
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–528.
   PubMed Web of Science ®Google Scholar
• Fong CY, Gilan O, Lam EY, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525:538–542.
   PubMed Web of Science ®Google Scholar
• Bai L, Zhou B, Yang CY, et al. Targeted degradation of BET proteins in triple-negative breast Cancer. Cancer Res. 2017;77:2476–2487.
   PubMed Web of Science ®Google Scholar
• Raina K, Lu J, Qian Y, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2016;113:7124–7129.
   PubMed Web of Science ®Google Scholar
• Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10:1770–1777.
   PubMed Web of Science ®Google Scholar
• Neklesa TK, Winkler JD, Crews CM. Targeted protein degradation by PROTACs. Pharmacol Ther. 2017;174:138–144.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16:101–114.
   PubMed Web of Science ®Google Scholar
• Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26:484–498.
   PubMed Web of Science ®Google Scholar
• Schneekloth JS, Jr., Crews CM. Chemical approaches to controlling intracellular protein degradation. Chembiochem. 2005;6:40–46.
   PubMed Web of Science ®Google Scholar
• Lee H, Puppala D, Choi EY, et al. Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool. Chembiochem. 2007;8:2058–2062.
   PubMed Web of Science ®Google Scholar
• Cyrus K, Wehenkel M, Choi EY, et al. Two-headed PROTAC: an effective new tool for targeted protein degradation. Chem Eur Jo F Chem Bio. 2010;11:1531–1534.
   Google Scholar
• Sakamoto KM. Protacs for treatment of cancer. Pediatr Res. 2010;67:505–508.
   PubMed Web of Science ®Google Scholar
• Carmony KC, Kim KB. PROTAC-induced proteolytic targeting. Methods Mol Biol. 2012;832:627–638.
   PubMedGoogle Scholar
• Bondeson DP, Crews CM. Targeted protein degradation by small molecules. Annu Rev Pharmacol Toxicol. 2017;57:107–123.
   PubMed Web of Science ®Google Scholar
• Lu J, Qian Y, Altieri M, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22:755–763.
   PubMedGoogle Scholar
• Skaar JR, Pagan JK, Pagano M. SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov. 2014;13:889–903.
   PubMed Web of Science ®Google Scholar
• Burgess A, Chia KM, Haupt S, et al. Clinical overview of MDM2/X-targeted therapies. Front Oncol. 2016;6:7.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liao YM, Hsueh CT, et al. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011;4:16.
   PubMed Web of Science ®Google Scholar
• Azmi AS, Philip PA, Aboukameel A, et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. CCDT. 2010;10:319–331.
   Google Scholar
• Zhao Y, Liu L, Sun W, et al. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 2013;135:7223–7234.
   PubMed Web of Science ®Google Scholar
• Buckley DL, Gustafson JL, Van Molle I, et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1alpha. Angew Chem Int Ed. 2012;51:11463–11467.
   PubMed Web of Science ®Google Scholar
• Buckley DL, Van Molle I, Gareiss PC, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc. 2012;134:4465–4468.
   PubMed Web of Science ®Google Scholar
• Cai Q, Sun H, Peng Y, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54:2714–2726.
   PubMed Web of Science ®Google Scholar
• Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109–124.
   PubMed Web of Science ®Google Scholar
• Fulda S. Novel promising IAP antagonist on the horizon for clinical translation. J Med Chem. 2012;55:4099–4100.
   PubMed Web of Science ®Google Scholar
• Lu J, Bai L, Sun H, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008;68:9384–9393.
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–681.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhu L, Cao Y, et al. ASD: a comprehensive database of allosteric proteins and modulators. Nucleic Acids Res. 2011;39:D663–D669.
   PubMed Web of Science ®Google Scholar